Advertisement

Cancer Imaging

, 15:P14 | Cite as

Radiogenomics of glioblastoma: a window into its imaging and molecular variability

  • A Mahajan
  • A V Moiyadi
  • R Jalali
  • E Sridhar
Poster presentation

Keywords

Histological Diagnosis Content Organisation Biochemical Feature Learn Objective Diagnostic Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Learning objectives

Gliomas, the most frequent tumours occurring in the CNS, are defined and graded on the basis of histological features to predict prognosis and management. Owing to biological heterogeneity, the histological diagnosis and expected clinical outcome do not match in a significant number of patients. The combination of imaging and gene expression, referred to as “radiogenomics,” has the potential to give insight into tumour biology that would be difficult to acquire from either technique alone.

  • Throwing light upon individual imaging feature and biological/ molecular alterations, analyses that may detect subsets of morphologically identical tumours with different clinical behavior (diagnostic markers).

Content organisation

  • Classification and grading of Gliomas as per Haarlem consensus.

  • Imaging features of glioblastomas may correlate with molecular mutations.

  • Identification of imaging parameters that has the potential as a non-invasive biomarker for common molecular mutations associated with gliomas and their associated clinical impact.

  • Review of current radiogenomics literature.

Conclusion

  • Given the noninvasive nature of medical imaging and its wide use in clinical practice this approach facilitates the association of complex molecular signatures with readily identifiable imaging characteristics.

  • As we move toward a more individualised approach to therapy for glioblastoma on the basis of its specific genetic and biochemical features, radiologists may contribute to the future development of targeted agents for treatment of glioblastoma.

Copyright information

© Mahajan et al. 2015

This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.

Authors and Affiliations

  1. 1.Tata Memorial CentreMumbaiIndia

Personalised recommendations